Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

ruxolitinib phosphate

(RUK-soh-LIH-tih-nib FOS-fayt)
A drug used to treat adults with certain types of primary myelofibrosis (MF), post-polycythemia vera MF, post-essential thrombocythemia MF, or polycythemia vera, and adults and children aged 12 years and older with acute or chronic graft-versus-host disease. It is also being studied in the treatment of some types of cancer. Ruxolitinib phosphate blocks a protein called JAK, which may help keep abnormal blood cells or cancer cells from growing. It may also lower the body’s immune response. Ruxolitinib phosphate is a type of tyrosine kinase inhibitor. Also called Jakafi.
More Information
Search NCI's Dictionary of Cancer Terms